Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 3;8:749863. doi: 10.3389/fmed.2021.749863

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Cai, Qiu, Ma, Zhang and Fan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

¹⁸F-FDG PET/CT images of the PBL patient at various stages of treatment. (A) Transverse PET/CT scan showed a markedly FDG-avid mass at the left maxillary sinus that invaded the left nasal cavity, left orbital apex, and left alar mandibular space at diagnosis (SUV_max, 7.8; SUV_mean, 6.3). (B) After five cycles of V-CHOP, re-evaluating PET/CT showed diminished range of lesions to 3.8 cm × 2.9 cm × 3.8 cm and reduced ¹⁸F-FDG uptake in the left maxillary sinus (SUV_max, 7.0; SUV_mean, 4.5) and other locations (SUV_max, 4.0; SUV_mean, 3.6). (C) After local radiotherapy and two cycles of RV-CDOP, PET/CT showed a complete metabolic response (cMR) with a diminished range of lesions to 1.0 cm × 1.3 cm and significantly reduced 18F-FDG uptake in the left maxillary sinus (SUV_max, 3.5; SUV_mean, 2.5) and a lack of metabolic activity in other regions. (D) Follow-up PET-CT 16 months post ASCT showed continued cMR.